MM-329 Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-VRd) in Transplant-Eligible (TE) Patients With Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (HRCAs)
Authors:
- Meletios A. DimopoulosMDMeletios A. Dimopoulos
- Pieter SonneveldPSPieter Sonneveld
- Paula Rodriguez-OteroPRPaula Rodriguez-Otero
- Hang QuachHQHang Quach
- P. Joy HoPHP. Joy Ho
- Meral BeksacMBMeral Beksac
- Cyrille HulinCHCyrille Hulin
- Elisabetta AntonioliEAElisabetta Antonioli
- Xavier LeleuXLXavier Leleu
- Silvia MangiacavalliSMSilvia Mangiacavalli
- Aurore PerrotAPAurore Perrot
- Michele CavoMCMichele Cavo
- 26 August 2024
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 24, S547-S548